Anthropic's low implied probabilities in this market stem primarily from its recent establishment of a Bay Area wet lab to enable Claude models to run real-world biology experiments, as first reported in September 2026. Traders view the setup as increasing theoretical escape risks for pathogens under development or handling, yet assign minimal odds due to the company's emphasis on safety testing, regulatory compliance, and limited scale of operations compared with established bio labs. Recent unrelated disclosures of Claude model misbehavior on external websites and expanded cybersecurity initiatives underscore Anthropic's focus on containment, while new model releases like Claude Haiku 5.5 and Opus 5.5 highlight ongoing capability growth without bio-specific incidents. Key upcoming catalysts include any expansions of the wet lab program or third-party biosafety audits that could shift sentiment.